

Sexual Function and Gonadal Hormones in Patients Taking Antipsychotic Treatment for Schizophrenia or Schizoaffective Disorder

Oliver D. Howes, M.R.C.Psych.; Michael J. Wheeler, M.R.C.P.;
Lyn S. Pilowsky, Ph.D.; Sabine Landau, Ph.D.;
Robin M. Murray, D.Sc.; and Shubulade Smith, M.R.C.Psych.

Objective: To determine rates of sexual dysfunction and hypogonadism and establish the relationship between gonadal hormone levels and sexual function in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder.

Method: We studied 103 patients with schizophrenia or schizoaffective disorder (mean age = 46.2 (SD = 12.9) years; 51.5% male) from October 2003 through March 2005. Sexual function was assessed using the Sexual Functioning Questionnaire (SFQ) and compared with (1) normal controls (N = 62; mean age = 36.1 (SD = 9.6) years; 55% male) recruited from primary care attendees and (2) sexually dysfunctional controls recruited from a local sexual dysfunction clinic (N = 57; mean age = 39.1 (SD = 10.7) years; 79% male). Prolactin, sex hormone-binding globulin, testosterone, estradiol, progesterone, follicle-stimulating hormone, and luteinizing hormone levels; psychopathology; and side effects were measured.

Results: Mean (SD) total SFQ scores were significantly greater in patients (women = 9.9 [5.3]; men = 7.8 [4.9]) compared with normal controls (women = 4.1 [2.9]; men = 4.09 [2.95]), and similar to the scores of sexual dysfunction clinic attendees (women = 7.2 [2.9]; men = 9.9 [4.5]). The odds ratios of patients having sexual dysfunction compared with normal controls were 15.2 for women and 3.7 for men. Hypogonadism was common (in premenopausal women, 79% showed hypoestrogenism and 92% showed low progesterone levels, and 28% of men showed hypotestosteronism). There was no association between total SFQ scores and prolactin or gonadal hormone levels.

Conclusion: Patients receiving treatment for schizophrenia or schizoaffective disorder show high rates of sexual dysfunction and hypogonadism. Sexual functioning was not related to prolactin or gonadal hormone levels.

(*J Clin Psychiatry* 2007;68:361–367)

Received Feb. 28, 2006; accepted Aug. 4, 2006. From the Institute of Psychiatry (Drs. Howes, Pilowsky, Murray, and Smith); the Department of Chemical Pathology, St. Thomas' Hospital (Dr. Wheeler); and the Department of Biostatistics, the Institute of Psychiatry (Dr. Landau) London, United Kingdom.

Funded by an investigator-led charitable research grant from AstraZeneca, London, United Kingdom.

This study has not been previously presented or published.

Dr. Murray's department has received his lecture fees and research grants from most major pharmaceutical companies; Dr. Murray has received grant/research support from Eli Lilly; has received honoraria from Eli Lilly, Janssen, and AstraZeneca; and serves on the speakers or advisory boards for Bristol-Myers Squibb and GlaxoSmithKline. Dr. Smith has received grant/research support from AstraZeneca; has received honoraria from Bristol-Myers Squibb, Otsuka, and Eli Lilly; and serves on the speakers or advisory boards for Eli Lilly and AstraZeneca. Drs. Howes, Wheeler, Pilowsky, and Landau report no other financial relationships relevant to this article.

Corresponding author and reprints: Oliver D. Howes, M.R.C.Psych., Institute of Psychiatry, Box 67, De Crespigny Park, London, SE5 8AF, U.K. (e-mail: O.Howes@iop.kcl.ac.uk).

Sexual dysfunction is common in patients taking antipsychotics—more than twice as common as in healthy controls^{1,2} and greater in patients taking antipsychotics than unmedicated schizophrenic patients and patients with affective disorders.^{3–5} The CATIE study has recently highlighted that sexual function is commonly impaired in patients taking atypical as well as typical antipsychotic treatment.⁶ A number of factors may play a role in impairing sexual function in patients taking antipsychotic treatment, including negative and comorbid depressive symptoms, the anticholinergic and adrenergic effects of antipsychotics, and higher rates of smoking and physical illness.^{2,7} It has long been supposed, however, that prolactin elevation and low gonadal hormone levels are significant factors underlying the high rates of sexual dysfunction seen in patients treated with antipsychotics.^{8–10} Prolactin may impair sexual function through its actions on the hypothalamic-pituitary-gonadal axis altering sex hormone release. Hyperprolactinemia is associated with hypogonadism and sexual dysfunction,¹¹ although a preliminary naturalistic study of women taking antipsychotics found high but similar rates of reproductive dysfunction in normoprolactinemic and hyperprolactinemic groups.¹² Low sex hormone levels have been

reported in patients taking antipsychotics.^{13–16} We have previously reported high rates of sexual dysfunction and high rates of hypogonadism in patients taking antipsychotics,¹ but no previous studies have investigated the association between the 2 variables. We hypothesized that low sex hormone levels are associated with sexual dysfunction in patients taking antipsychotics.

We therefore set out to substantiate the finding that rates of sexual dysfunction are higher in patients taking antipsychotics than healthy controls in a larger sample and to test the hypothesis that sexual dysfunction is associated with prolactin and gonadal hormone levels in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder.

METHOD

Study Design and Setting

A cross-sectional design was used. The Institute of Psychiatry Research Ethics committee approved the study. After complete description of the study, subjects gave written informed consent.

Sample

Patients were recruited by direct approach of the investigators (O.D.H., S.S.) from an inner-city community mental health team (catchment area N = 272,000) from October 2003 through March 2005. Consecutive outpatient attendees were invited to participate (16 declined, 3 were excluded, and 103 participated; mean age = 46.2 [SD = 13.0] years; 52% male). Inclusion criteria were 18 to 65 years of age, diagnosed with schizophrenia or schizoaffective disorder according to DSM-IV criteria, and stabilized on antipsychotic medication for greater than 6 months. Consecutive attendees at a general practice clinic (N = 62; mean age = 36.1 [SD = 9.6] years; 55% male) and a general hospital sexual dysfunction clinic (N = 57; mean age = 39.1 [SD = 10.7] years; 79% male), both within the same catchment area served by the mental health team, were used as “healthy” and “ill” controls, respectively, for the assessment of sexual functioning, as previously described.¹

The controls did not receive the hormonal measures. Exclusion criteria for all groups were medical/physiologic/psychiatric cause of gonadal or sexual dysfunction (e.g., depression, vascular disease related to smoking or other causes, renal failure, hypothyroidism, pregnancy or lactation, Cushing’s disease, diabetes mellitus, and drug treatments, e.g., antidepressants, exogenous hormones), and for the control groups, exclusion criteria were any history of abnormal menses or endocrine disorder. All groups gave smoking, substance use, and alcohol use histories, and subjects were excluded if dependent on a substance other than nicotine (pathology related to smoking that might affect sexual dysfunction was an exclusion criterion). The sexual

dysfunction clinic controls received a full assessment to exclude endocrine causes of sexual dysfunction.

Procedure

Demographic and clinical data, including menstrual function using the STRAW guidelines,¹⁷ was obtained by a semistructured assessment as previously described.¹⁸ Antipsychotic doses were converted to chlorpromazine equivalents using established criteria.^{19,20} Subjects completed the short Sexual Functioning Questionnaire (SFQ), a self-report structured instrument that has been previously validated in patients with psychotic disorders.¹ The SFQ includes subscales assessing libido, physical arousal, erectile function, orgasm, and ejaculatory function. Higher scores indicate greater impairment, and a total SFQ score ≥ 8 is the cutoff indicating sexual dysfunction.

A psychiatrist (O.D.H.) rated psychopathology and side effects, as these may influence sexual function,¹ using the following measures, having been previously trained in their application:

1. Structured Clinical Interview for the Positive and Negative Syndrome Scale (PANSS)²¹
2. Abnormal and Involuntary Movement Scale (AIMS)²²
3. Simpson-Angus Scale (SAS)²³
4. Anticholinergic and adrenergic side effects section of the UKU side effect rating scale²⁴
5. Barnes Akathisia Scale²⁵
6. Calgary Depression Scale²⁶

Hormone Measurement

Blood samples were taken between 11:00 a.m. and midday, 30 minutes after insertion of a cannula (to reduce transient stress effects). Subjects omitted all medication for at least 12 hours, or 7 days in the case of depot medications, prior to assessment. Menstruating women were tested during the luteal phase of their cycle. Serum levels of estradiol, progesterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, sex hormone-binding globulin (SHBG), thyroid-stimulating hormone (TSH), and testosterone were measured using chemiluminescent immunoassays (ADVIA Centaur, Bayer Diagnostics, Los Angeles, Calif.). Thyroid-stimulating hormone levels were measured, as high levels of TSH may alter SHBG and sex hormone levels.²⁷ Intra- and inter-assay variation was $< 12.5\%$ for progesterone, TSH, sex hormone-binding globulin, and estradiol and $< 7\%$ for the other assays across all the concentration ranges studied. Free testosterone levels were derived using the method described by Nanjee and Wheeler.²⁸

Statistical Analysis

Men and women were analyzed separately. All statistical tests were 2-tailed.

Analysis of sexual function across groups. The analysis compared sexual function (measured using the SFQ) between the healthy controls, sexually dysfunctional controls, and patients. The SFQ total and subscale scores were compared across groups using an analysis of variance adjusting for age and menopausal status in women, as these variables are recognized determinants of sexual function.^{29–31} Where the F-test showed an overall group difference, pairwise post hoc comparisons were carried out to evaluate individual group differences. A conservative 1% significance level was applied because of the multiple tests, and this was made more stringent for the post hoc tests by dividing the significance level by the number of post hoc tests (Bonferroni correction).

Analysis of the relationship between sexual function and hormonal measures in patients. Hormonal abnormalities were defined in accordance with the hospital laboratory reference range (prolactin level > 480 mIU/L indicating hyperprolactinemia; total testosterone level < 9 nmol/L in men indicating hypotestosteronism; and, in women, estradiol levels < 365 pmol/L indicating hypoestrogenism and progesterone levels < 30 nmol/L indicating hypoprogesteronism) and are presented separately for postmenopausal and premenopausal women, using the STRAW criteria for determining menopausal status.¹⁷ The percentage of the sample showing abnormal levels is reported for each hormonal measure after excluding subjects with missing data. Linear regression was used to test the hypothesis that sexual function was related to hormonal factors, using SFQ total score as the dependent variable and age and hormonal levels as the independent variables. Side effect and psychopathology levels and menstrual status were entered as additional independent variables.

RESULTS

Demographic and Clinical Variables

The mean (SD) ages of the healthy controls, sexual dysfunction clinic controls, and patients were 36.1 (9.6), 39.1 (10.7), and 46.2 (12.9) years, respectively. As sexual dysfunction is more common in older people, comparisons between groups were adjusted for age. Patients were taking the following antipsychotics: amisulpride (N = 11), chlorpromazine (N = 5), flupentixol (N = 23), fluphenazine (N = 5), haloperidol (N = 9), pimozide (N = 1), pipotiazine (N = 2), risperidone (N = 8), sulpiride (N = 3), trifluoperazine (N = 7), zuclopenthixol (N = 9), olanzapine (N = 18), quetiapine (N = 1), and ziprasidone (N = 1). The mean dose of antipsychotic treatment expressed as chlorpromazine equivalents was 355 (SD = 321) mg, and median treatment duration was 3.3 years (interquartile range = 8.5). Patients were taking the following additional medication: anticholinergics (procyclidine [N = 28], orphenadrine [N = 8], benzhexol [N = 1]), mood stabilizers (lithium [N = 4], valproate [N = 7],

carbamazepine [N = 4]), and hypnotics (diazepam [N = 10], zopiclone [N = 1]).


In the patient group, the mean (SD) PANSS total, PANSS negative subscale, and Calgary Depression Scale scores were 44.1 (11.9), 12.8 (5.4), and 2.6 (3.8), respectively, indicating good symptom control. Their mean Barnes, Angus Simpson, AIMS, and UKU scale (anticholinergic and adrenergic section) side effect scores were 2.5 (3.8), 2.4 (5.0), 1.9 (3.8), and 5.6 (5.0), respectively, indicating low levels of these side effects. Fifty percent (N = 52) of the patients were smokers (median consumption = 15 [interquartile range = 10–30] cigarettes/day), 47% (N = 48) drank alcohol (median 6.0 units/week [interquartile range = 2.0–13.5]), and mean BMI was 29 (SD = 9.8) kg/m². In the women (N = 50), the lifetime median number of pregnancies was 2 (interquartile range = 0–4), total median time breastfeeding was 0 months (interquartile range = 0–3), and none were currently pregnant or lactating. Twenty-one were postmenopausal, and 29 were premenopausal, of whom 6 were oligomenorrheic. All of the controls were premenopausal and none reported menstrual disturbance.

Sexual Function

Mean total SFQ scores were higher, indicating poorer sexual functioning, in the female and male patients compared with healthy controls and were also higher in the female, but not male, patients compared with sexual dysfunction clinic controls (Figure 1). Table 1 shows the group analysis, indicating that there was a significant effect of group on sexual function for men and women across all the domains of sexual function. Post hoc comparisons in the men indicate that sexual function scores were significantly higher in the patient group compared with the healthy controls across all domains (mean difference [95% confidence interval] for libido = 1.2 [0.5 to 1.8], $p < .001$; erectile function = 1.4 [0.6 to 2.1], $p < .001$; arousal = 1.02 [0.4 to 1.6], $p = .001$; and total score = 3.5 [1.5 to 5.4], $p = .001$) except for ejaculatory function (0.3 [–0.4 to 1.03], $p = .5$). In women, sexual function scores were higher across all domains (mean difference [95% confidence interval] for libido = 2.6 [1.3 to 3.8], $p < .001$; orgasmic function = 1.4 [0.4 to 2.4], $p = .006$; and total score = 5.8 [2.3 to 9.3], $p = .002$) except arousal (0.6 [–0.3 to 1.5], $p = .2$). At the corrected significance level, there was no significant difference between patients and sexual dysfunction clinic controls in the men (mean difference [95% confidence interval] in total score = –2.2 [4 to 0.3], $p = .02$) or women (total score = 2.7 [–1.4 to 6.9], $p = .19$).

According to the SFQ cutoff for sexual dysfunction, 68% of female patients and 52% of male patients showed sexual dysfunction, compared with 14% and 22% of controls respectively. The unadjusted odds ratio of patients having sexual dysfunction compared to healthy controls

Figure 1. Sexual Function (mean [SD] SFQ score) in Patients Taking Antipsychotics, Healthy Controls, and Sexually Dysfunctional Controls^a



^aHigher SFQ score indicates greater dysfunction. Compared with healthy controls, patients show significantly greater sexual dysfunction across all domains except arousal (female) and ejaculatory function (male), and similar SFQ scores to sexual dysfunction controls.

* $p < .01$.

Abbreviation: SFQ = Sexual Functioning Questionnaire.

Table 1. Analysis of Sexual Function (Sexual Functioning Questionnaire total and subdomain scores) by Group Showing a Significant Effect of Group Across All Domains for Men and Women

Sexual Function	Degrees of Freedom	F Statistic	p Value
Libido			
Men	2,124	6.8	.002
Women	2,67	7.9	.001
Arousal			
Men	2,122	10.4	< .001
Women	2,66	5.6	.006
Erectile function (men)	2,121	15.8	< .001
Ejaculatory function (men)	2,114	7.9	.001
Orgasmic function (women)	2,62	7.5	.001
Total			
Men	2,112	16.6	< .001
Women	2,51	7.0	.002

was 15.2 (95% CI = 3.84 to 60.2) for women and 3.7 (95% CI = 1.7 to 13.9) for men.

Hormonal Measures

Mean (SD) TSH levels (men = 1.3 [0.85] mIU/L and women = 1.8 [2.0] mIU/L) were within the normal range and none indicated hypothyroidism.

The distributions of gonadal hormones showed a positive skew in the women and are therefore presented

as median values (Table 2). Of premenopausal women, 12 (48%) were hyperprolactinemic, 17 (79%) showed hypoestrogenism, and 9 (38%) showed severe hypoestrogenism (estradiol < 74 pmol/L). Twenty-three (92%) showed low progesterone levels (indicating intermittent anovulatory cycles), and 14 (56%) showed markedly low progesterone levels (< 2 nmol/L, indicating completely anovulatory cycles). Excluding those with oligomenorrhea, 76% of premenopausal women reporting regular menses showed low estradiol levels (median estradiol level = 68.2 pmol/L [interquartile range = 123.4]), much less than the lower limit of the range in the luteal phase (365–1100 pmol/L) and even lower than the range in the follicular phase (74–365 pmol/L). Similarly, they had median progesterone levels of 1.4 nmol/L (interquartile range = 4.22), much less than the lower limit of the range in the luteal phase (30–100 nmol/L) and even lower than the range in the follicular phase (2–8 nmol/L), and 90% showed low progesterone levels. In postmenopausal women, 11 (52.6%) showed hyperprolactinemia, although progesterone and estradiol levels were within normal postmenopausal ranges.

Gonadal hormone levels were normally distributed in the men (Table 2). Hyperprolactinemia was present in 9 (19%) men. Thirteen men (28%) had total testosterone

Table 2. Hormone Levels in Patients Taking Antipsychotics

Patients	Prolactin (mIU/L)	Estradiol (pmol/L)	Progesterone (nmol/L)	Follicle- Stimulating Hormone (IU/L)	Luteinizing Hormone (IU/L)	Total Testosterone (nmol/L)	Free Testosterone (pmol/L)
Premenopausal women (N = 29)							
Median (IQR)	480* (240–1563)	142* (26.5–324.3)	1.3* (0.8–17.1)	4.4 (3.2–11.7)	5.9 (2.2–11.3)	1.3 (0.8–1.7)	19.2 (8.9–23)
Reference range	< 480	365–1100	30–100	2.6–9.1	1.1–12.1	0.5–2.5	10–50
Postmenopausal women (N = 21)							
Median (IQR)	505* (193–2160)	37 (17.3–60)	1.2 (0.8–1.5)	49.7 (15.0–65.7)	24.2 (8.2–30.6)	1.6 (1.1–1.8)	21.8 (9.2–33.5)
Reference range	< 480	< 174	< 2.5	43.7–106	13.2–45.7	0.5–2.5	10–50
Men (N = 53)							
Mean (SD)	360 (258)	56.7 (36.8)	NA	4.1 (2.3)	4.2 (2.2)	13.8 (6.8)	352.3 (154.5)
Reference range	< 480	< 174		1.8–8.6	0.8–6.1	9.0–30.0	134–844

*Results outside of the reference range.

Abbreviation: IQR = interquartile range, NA = not applicable.

Table 3. Results of Linear Regression of Hormonal Measures on Total Sexual Function Score in Men and Women Taking Antipsychotics

Hormonal Measure	Degrees of Freedom	F statistic	p Value*
Prolactin			
Men	2,32	1.2	.3
Women	2,30	0.5	.6
Free testosterone			
Men	2,32	1.7	.2
Women	2,31	0.3	.8
Total testosterone			
Men	2,32	1.5	.2
Women	2,31	0.9	.4
Estradiol			
Men	2,32	1.6	.2
Women	2,31	1.3	.3
Progesterone (women)	2,31	0.5	.6

*Hormonal level has no significant effect on Sexual Functioning Questionnaire score (adjusted for multiple comparisons).

levels below the lower limit of the normal range, and 2 (4%) had free testosterone levels below this range.

Relationship Between Hormonal Measures and Sexual Function in Patients

Table 3 shows the results of the linear regression analysis testing the hypothesis that sexual function is associated with prolactin and gonadal hormones. The analysis indicates that there is no association between total SFQ score and prolactin or the gonadal hormones measured in male or female patients. This remained the case after adjusting for side effect and psychopathology levels, BMI, and antipsychotic class (typical/atypical). In women, entering menopausal status as a covariate or analyzing premenopausal women with regular menses as a separate group made no difference.

DISCUSSION

This study is the first study we are aware of to examine the relationship between sexual function and gonadal

hormone levels in patients taking antipsychotics and the largest to systematically assess sexual function in patients taking antipsychotic drugs.

High rates of sexual dysfunction were found in patients, and their sexual function was impaired compared with healthy controls and indeed was similar to that seen in attendees at a sexual dysfunction clinic, indicating that clinically significant sexual dysfunction is common in patients taking antipsychotics. High rates of hyperprolactinemia and hypogonadism were found in men and women. Ninety-two percent of premenopausal women and 28% of men showed biochemical hypogonadism. Estradiol and progesterone levels were found to be much lower than the normal reference range in premenopausal women and approached those of the postmenopausal women, indicating impaired ovulation and fertility. Of the premenopausal women, over half showed progesterone levels that were very low: below the lower limit of the progesterone range in the follicular phase; and over a third showed estradiol levels below the lower limit of the range in the follicular phase. This is particularly striking as samples were taken in the luteal phase when progesterone and estradiol levels should be higher than the follicular phase. These results are in keeping with other studies indicating that sexual dysfunction and low gonadal hormone levels are common in patients taking antipsychotics^{2,13,16} and extend earlier research by finding that there is no relationship between sexual function and prolactin or gonadal hormone levels in this group.

Methodological Considerations

The large size and representativeness of the sample are strengths of the study. However, a number of methodological issues need to be considered. The study is cross-sectional so the direction of causality cannot be determined, and a number of factors that we were unable to control for may contribute to the observation of high rates of hypogonadism and sexual dysfunction. Hypogonadism and sexual dysfunction may be intrinsic to schizophrenia,

although normal prolactin levels, sex hormone levels, and sexual function have been found in unmedicated patients with schizophrenia.^{3,14,32,33}

The finding of low estrogen in women reporting regular menstrual cycles should be treated cautiously, as there is a possibility of errors in recording menstrual diaries (meaning higher rates of oligomenorrhea/amenorrhea), although women with apparently regular menstruation can show anovulatory cycles associated with low estrogen levels spontaneously or in association with hyperprolactinemia.³⁴ Longitudinal studies would be useful to evaluate this further.

Testosterone shows a diurnal variation, peaking in healthy controls between 7:00 a.m. and 9:00 a.m.³⁵ In this study, samples were taken between 11:00 a.m. and midday and may have missed peak levels, although this was done because subjects typically slept until mid-morning, and schizophrenia is associated with reduced diurnal variation.^{36–38}

Current depressive disorder was excluded and levels of depressive symptoms were low, indicating that the high rates of sexual dysfunction are unlikely to be secondary to depression. Antimuscarinic medication and mood stabilizers may affect sexual function and could have contributed to the higher rates in our subjects, although these drugs are unlikely to result in hypogonadism. Obesity and smoking may affect sexual function and sex hormone levels and may be more common in patients than the general population. However, as smoking tends to increase testosterone and reduce estradiol levels and obesity has the opposite influences, the net effect is unlikely to explain the high rates of hypogonadism we observed.^{39–41}

The CATIE trial has recently highlighted the high rates of hypertension and diabetes in patients taking antipsychotics, both associated with sexual dysfunction.⁴² We excluded hypertension and diabetes in our sample through clinical assessment and blood pressure measurement, which may indicate that rates of sexual dysfunction will be higher in unselected patients. However, prediabetic states may have been missed and could be contributing to the high rate of sexual dysfunction in our patients through microvascular damage. It is possible that perimenopausal women were misclassified. However, repeating the analyses in the group of premenopausal women with regular menses made no difference, indicating that misassignment of menopausal status is unlikely to explain the high rates of hypogonadism or the absence of a relationship between hormonal levels and SFQ scores.

It is possible that the null hypothesis has been falsely accepted and there is in fact an association between sex function and sex hormones or prolactin (type II error). However, the power calculation indicates the sample size has over 95% power to detect a relationship explaining 30% or more of the variance and 80% power to detect a relationship explaining 17% or more of the variance when

$\alpha = .05$. It is possible that the association is nonlinear, for example showing a threshold effect, but this was not apparent when the data were plotted, and there was no evidence of threshold effects (for example, an association in a hyperprolactinemic subgroup only).

Clinical and Research Implications

The high rates of hypogonadism are of particular concern given the association between low sex hormone levels and osteoporosis, infertility, and cardiovascular disease.⁴³ Low sex hormone levels have also been linked with exacerbation of psychotic symptoms in patients with schizophrenia.^{15,16,44}

Sexual dysfunction and side effects are a major concern to patients, although often neglected by clinicians and linked to nonadherence to antipsychotic treatment.^{29,45} The low psychopathology and side effect rating scores in the sample demonstrate that sexual dysfunction may be present even in stable patients treated with low to moderate doses of antipsychotics. The absence of an association between hormone levels and SFQ scores highlights that the etiology of sexual dysfunction in patients taking antipsychotics is likely to be complex and suggests that a model involving the interaction of multiple psychological, social, and pharmacologic factors is needed. Antipsychotics could contribute directly through adrenergic and cholinergic mechanisms and indirectly by increasing the likelihood of other risk factors for sexual dysfunction, such as diabetes mellitus.

Conclusions

Our findings confirm that clinically significant sexual dysfunction and hypogonadism are common in patients taking antipsychotics and indicate that prolactin and gonadal hormone levels are unlikely to be major etiologic factors. The high rates of hypogonadism suggest that patients are at increased risk of cardiovascular disease and osteoporosis. Clinicians are advised to enquire about sexual dysfunction and monitor prolactin and gonadal hormone levels in patients taking antipsychotics. Future research, ideally randomly assigning drug-naïve patients to treatment with antipsychotics showing different dopaminergic, cholinergic, and adrenergic activity profiles, is needed to further tease apart the pharmacologic, psychological, and social etiologic factors and guide treatment choice for the large proportion of patients taking antipsychotics who show sexual dysfunction and low sex hormone levels.

Drug names: carbamazepine (Carbatrol, Equetro, and others), chlorpromazine (Thorazine, Sonazine, and others), diazepam (Valium and others), fluphenazine (Prolixin and others), haloperidol (Haldol and others), lithium (Eskalith, Lithobid, and others), olanzapine (Zyprexa), orphenadrine (Norflex and others), pimozide (Orap), procyclidine (Kemadrin), quetiapine (Seroquel), risperidone (Risperdal), trifluoperazine (Stelazine and others), ziprasidone (Geodon), zopiclone (Lunesta).

REFERENCES

- Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. *Br J Psychiatry* 2002;181:49–55
- Macdonald S, Halliday J, MacEwan T, et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction: case-control study. *Br J Psychiatry* 2003;182:50–56
- Kockott G, Pfeiffer W. Sexual disorders in nonacute psychiatric outpatients. *Compr Psychiatry* 1996;37:56–61
- Aizenberg D, Zemishlany Z, Dorfman-Etrog P, et al. Sexual dysfunction in male schizophrenic patients. *J Clin Psychiatry* 1995;56:137–141
- Blair JH, Simpson GM. Effect of antipsychotic drugs on reproductive functions. *Dis Nerv Syst* 1966;27:645–647
- Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005;353:1209–1223
- Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? *Psychoneuroendocrinology* 2003;28(suppl 2):109–123
- Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. *J Nerv Ment Dis* 1982;170:463–467
- Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. *Drugs* 2004;64:2291–2314
- Cutler AJ. Sexual dysfunction and antipsychotic treatment. *Psychoneuroendocrinology* 2003;28(suppl 1):69–82
- Bancroft J. Endocrinology of sexual function. *Clin Obstet Gynaecol* 1980;7:253–281
- Canuso CM, Goldstein JM, Wojcik J, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. *Psychiatry Res* 2002;111:11–20
- Smith S, Wheeler MJ, Murray R, et al. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. *J Clin Psychopharmacol* 2002;22:109–114
- Baptista T, Reyes D, Hernandez L. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation. *Pharmacol Biochem Behav* 1999;62:409–417
- Huber TJ, Tettenborn C, Leifke E, et al. Sex hormones in psychotic men. *Psychoneuroendocrinology* 2005;30:111–114
- Huber TJ, Borsutzky M, Schneider U, et al. Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis. *Acta Psychiatr Scand* 2004;109:269–274
- Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). *Fertil Steril* 2001;76:874–878
- Howes OD, Wheeler MJ, Meaney AM, et al. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. *J Clin Psychopharmacol* 2005;25:259–261
- Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. *J Clin Psychiatry* 2003;64:663–667
- Rey MJ, Schulz P, Costa C, et al. Guidelines for the dosage of neuroleptics, 1: chlorpromazine equivalents of orally administered neuroleptics. *Int Clin Psychopharmacol* 1989;4:95–104
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull* 1987;13:261–276
- Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. *ECDEU Assessment Manual for Psychopharmacology*, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534–537
- Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. *Acta Psychiatr Scand Suppl* 1970;212:11–19
- Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. *Acta Psychiatr Scand Suppl* 1987;334:1–100
- Barnes TR. A rating scale for drug-induced akathisia. *Br J Psychiatry* 1989;154:672–676
- Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. *Schizophr Res* 1992;6:201–208
- Meikle AW. The interrelationships between thyroid dysfunction and hypogonadism in men and boys. *Thyroid* 2004;14(suppl 1):S17–S25
- Nanjee MN, Wheeler MJ. Plasma free testosterone—is an index sufficient? *Ann Clin Biochem* 1985;22:387–390
- Stevenson RW. Sexual medicine: why psychiatrists must talk to their patients about sex. *Can J Psychiatry* 2004;49:673–677
- Avis NE. Sexual function and aging in men and women: community and population-based studies. *J Gend Specif Med* 2000;3:37–41
- Guay A, Munarriz R, Jacobson J, et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction, pt A: serum androgen levels in women aged 20–49 years with no complaints of sexual dysfunction. *Int J Impot Res* 2004;16:112–120
- Ozcan ME, Banoglu R. Gonadal hormones in schizophrenia and mood disorders. *Eur Arch Psychiatry Clin Neurosci* 2003;253:193–196
- Segal M, Avital A, Rojas M, et al. Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes. *Psychiatry Res* 2004;127:227–235
- Fraser IS, Michie EA, Wide L, et al. Pituitary gonadotropins and ovarian function in adolescent dysfunctional uterine bleeding. *J Clin Endocrinol Metab* 1973;37:407–414
- Diver MJ. Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men. *Ann Clin Biochem* 2006;43:3–12
- Boivin DB. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. *J Psychiatry Neurosci* 2000;25:446–458
- Duncan E, Bollini AM, Sanfilippo M, et al. Diurnal variation in plasma homovanillic acid in patients with schizophrenia and healthy controls. *Schizophr Res* 2006;81:323–326
- Martin JL, Jeste DV, Ancoli-Israel S. Older schizophrenia patients have more disrupted sleep and circadian rhythms than age-matched comparison subjects. *J Psychiatr Res* 2005;39:251–259
- Sowers MF, Beebe JL, McConnell D, et al. Testosterone concentrations in women aged 25–50 years: associations with lifestyle, body composition, and ovarian status. *Am J Epidemiol* 2001;153:256–264
- Jensen TK, Andersson AM, Jorgensen N, et al. Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. *Fertil Steril* 2004;82:863–870
- Trummer H, Habermann H, Haas J, et al. The impact of cigarette smoking on human semen parameters and hormones. *Hum Reprod* 2002;17:1554–1559
- Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. *Schizophr Res* 2005;80:9–18
- Haddad PM. Antipsychotics and diabetes: review of non-prospective data. *Br J Psychiatry Suppl* 2004;47:S80–S86
- Huber TJ, Rollnik J, Wilhelms J, et al. Estradiol levels in psychotic disorders. *Psychoneuroendocrinology* 2001;26:27–35
- Finn SE, Bailey JM, Schultz RT, et al. Subjective utility ratings of neuroleptics in treating schizophrenia. *Psychol Med* 1990;20:843–848